Clinical

 is professor of surgery in the division of urology at Albany Medical College in New York.

Articles

"It is evident...that the safety of 5-ARIs as it relates to prostate cancer outcomes is contingent upon the clinician understanding its effect on PSA level and making appropriate adjustments to ensure timely deployment of diagnostic imaging and biopsy," writes Badar M. Mian, MD.

Do 5-ARIs protect against death from prostate cancer?

Videos

Stephen J. Freedland, MD, highlights emerging data to look out for that might address unmet needs in prostate cancer testing and treatment.

Exciting Emerging Data in Prostate Cancer

"This article serves as a summary of the literature published in the past 3 years, documenting the impact of exercise and physical activity on prostate cancer development and on cancer-specific, treatment-related, and patient-reported outcomes," writes Christine Ibilibor, MD, MSc.

The effects of exercise before and after a prostate cancer diagnosis

Dr Freedland discusses the clinical implications of using genomic test results for management of patients with prostate cancer.

Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection

A key opinion leader provides an overview of study data investigating the clinical validity and clinical utility of the currently available genomic testing options in prostate cancer.

Clinical Study Data in Prostate Cancer Genomic Testing

The FDA has granted 510(k) clearance to an artificial intelligence software program that may enhance the efficiency and accuracy of prostate cancer diagnosis.

FDA grants clearance to AI software for MRI detection of prostate cancer

The Avenda system combines the company’s proprietary iQuest AI-based margin prediction software algorithms with its FocalPoint laser ablation device.

FDA clears path for trial of AI-enabled focal therapy in prostate cancer

The rate of positive surgical margins was higher among patients who did not have a preoperative MRI.



Despite potential benefit, use of preoperative MRI low before radical prostatectomy

Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.

Unmet Needs and Investigational Therapies in mCSPC

Jason Hafron, MD, revisits the patient profile and discusses factors that inform treatment decision-making in mCSPC.